Combo therapy improves survival in kidney cancer

Combining Opdivo, an immunotherapy, and Cabometyx, a once-daily pill, improved the survival in kidney cancer patients when compared to the standard of care — an older treatment called sunitinib, the companies behind the two drugs said. 

Exelixis, the maker of the kinase inhibitor drug Cabometyx, said the combination reduced the risk of disease progression by 49%, and the risk of death by 40%. Bristol-Myers Squibb, which makes Opdivo, also said that combining the drug with another immunotherapy it sells, Yervoy, was stopped early because the treatments improved survival compared to chemotherapy. 

Read more.